qnexa

"The resounding vote of confidence from yesterday's FDA Advisory Committee meeting ... Vivus Inc. shares doubled Thursday after a federal advisory panel overwhelmingly backed the weight-loss drug Qnexa, clearing the way for U. S. approval of the first prescription diet drug in more than a decade. The drug still requires approval... - Source